


PRODUCT: GSK-LSD1 dihydrochloride**ALTERNATE NAME:** N-((1R,2S)-2-phenylcyclopropyl)piperidin-4-amine hydrochloride**CATALOG #:** B1258-5,25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₁₄H₂₂Cl₂N₂**MOLECULAR WEIGHT:** 289.24**CAS NUMBER:** 1431368-48-7 (free base)**APPEARANCE:** White to off-white solid**SOLUBILITY:** H₂O (>20 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20°C. Protect from air and moisture**DESCRIPTION:** GSK-LSD1 is a potent and selective inhibitor of lysine specific demethylase 1 (LSD1). GSK-LSD1 2HCl irreversibly inhibits LSD1 with IC₅₀ value of 16 nM and is > 1000 fold selective over LSD2, MAO-A and MAO-B, which were related to FAD utilizing enzymes. GSK-LSD1 potently inhibits proliferation of various cancer cell lines by changing gene expression patterns.**REFERENCES:** Mohammad, H.P., *et al.* (2015). *Cancer Cell* **28**, 57-69.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

AS8351 (Cat. No. B1082-5,25)

Caffeic acid (Cat. No. 2303-50, 250)

Clorgyline hydrochloride (Cat. No. 2622-10, 50)

Daminozide (Cat. No. 2438-100, 500)

Disulfiram (Cat. No. 2308-10, 50)

Ebselen (Cat. No. 2169-5, 25)

GSK-J4 hydrochloride (Cat. No. 2259-1, 5)

GSK-J4 (Free base) (Cat. No. 2762-1,5)

GSK-J1 sodium (Cat. No. 2260-1, 5)

GSK-J1 (Cat. No. 2761-1,5)

GSK-LSD1 hydrochloride (Cat. No. B1258-5,25)

Harmine (Cat. No. 2561-50, 250)

IOX1 (Cat. No. 2266-5, 25)

Jumonji HDM Inhibitor, JOB-04 (Cat. No. 2474-5, 25)

Jumonji HDM Inhibitor, PBIT (Cat. No. 2475-5, 25)

β-Lapachone (Cat. No. 2262-5, 25)

ML-324 (Cat. No. 2763-5, 25)

OG-L002 (Cat. No. 9406-5, 25)

Pargyline hydrochloride (Cat. No. 2618-500, 1000)

2,4-PDCA (Cat. No. 2304-100, 500)

Rasagiline mesylate (Cat. No. 2237-50, 250)

SP-2509 (Cat. No. 9446-5,25)

Tranlylcypromine hemisulfate (Cat. No. 1816-25, 100)

USAGE: **FOR RESEARCH CH USE ONLY! Not to be used in humans**